How long does it take to become resistant to Ponatinib?

Ponatinib (Ponatinib) is an oral pan-BCR-ABL1 inhibitor with potential activity in severely pretreated patients, including T315I mutations. In the long-term follow-up of the PACE trial, 60% of patients with prior TKI exposure had a major cytogenetic response and 40% had a major molecular response to ponatinib; the 5-year overall survival rate was 73%. Cardiovascular adverse events are the major toxicity associated with ponatinib. Ponatinib has been shown to be a potent inhibitor with clinical activity in both BCR-ABL wild-type and mutant chronic phase chronic myelogenous leukemia, including the pan-drug-resistant T315I mutation. However, ponatinib should be used with caution due to increased cardiovascular risk.